Introduction {#S0001}
============

Host defence peptides (HDPs) are an evolutionarily ancient component of the innate immune system of most multicellular organisms.[@CIT0001] They exhibit a wide range of biological activities from direct killing of invading pathogens to modulation of immunity and other biological responses of the host. In this article, we will refer to the overlapping classes of peptides with these activities as antimicrobial and immunomodulatory, respectively. Despite the enormous diversity in their sequences and structures, most HDPs share the following features: positive charge, high content of hydrophobic residues, and amphipathic fold.[@CIT0002] The structural diversity of natural peptides provides an excellent starting point for the production of artificial peptides and derivatives with more potent and desirable biological activities, for clinical and commercial applications.[@CIT0003]

The diversity of host defence peptides {#S0002}
======================================

Two major families of naturally occurring HDPs have been distinguished: defensins and cathelicidins ([Table 1](#T0001){ref-type="table"}). Defensins are cationic amphipathic peptides with an average length of 30 residues and a triple-stranded antiparallel b-sheet structure, stabilised by three disulphide bonds.[@CIT0004] Defensins are further subdivided into three subfamilies of α, β, θ defensins, based on the pattern of disulphidebonding ([Table 1](#T0001){ref-type="table"}).

###### 

The diversity of mammalian host defence peptides

  *Peptide family and structure*                                                                                 *Subfamily*                                                 *Expression and diversity*                                                                                                                                                                                                                                       
  -------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------- ------------------------------------------------------------------------------ ------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------
  *Defensin*                                                                                                     α-*defensins*                                               Neutrophils and other leukocytes                                               Paneth cells of the intestines Epithelial cells                                                                                                                                   No α-defensins
  Amphipathic, cationic peptides Triple-stranded antiparallel β-sheet                                            Three disulphide bonds linking cysteines 1--6, 2--4, 3--5   Paneth cells of the intestines Mucosal epithelia, skin                                                                                                                                                                                                           
                                                                                                                 β-defensins                                                 Mucosal epithelia and skin Monocytes, macrophages, dendritic cells             Epithelial cells                                                               Epithelial cells                                                                                   Epithelial cells Neutrophils and other leukocytes
                                                                                                                 Three disulphide bonds linking cysteines 1--5, 2--4, 3--6                                                                                                                                                                                                                                                                    
  *Cathelicidin*                                                                                                 Non-applicable                                              LL-37 expressed by neutrophils, and other leukocytes mucosal epithelia, skin   CRAMP expressed by neutrophils, and other leukocytes mucosal epithelia, skin   Large variety: protegrins, PR-39, prophenins, etc. Expressed by neutrophils and other leukocytes   Large variety: bactenecin, BMAP, indolicidin, etc. Expressed by neutrophils and other leukocytes
  Amphipathic, cationic peptides Diverse sequence and structure Cleaved from a cathelin-like precursor protein                                                                                                                                                                                                                                                                                                                                

In humans, but not in cattle or mice, α-defensins are found in the secretory granules of neutrophils and other leukocytes.[@CIT0005], [@CIT0006] In most mammals other than cattle, a set of α-defensins is also produced by Paneth cells in the crypts of the small intestine.[@CIT0007], [@CIT0008] These α-defensins, also known as cryptidins, are synthesised as inactive precursors and activated by a removal of an N-terminal segment catalysed by metalloprotease matrilysin (MMP7) in mice and by trypsin in humans.[@CIT0009], [@CIT0010] After microbial stimulation, the concentration of α-defensins within the crypts is estimated to reach 10 mg/ml, which is more than sufficient for strong microbicidal action.[@CIT0011] This, and the association of Crohn\'s disease with dysregulation in cryptidin production,[@CIT0012] highlights the importance of a-defensins in the maintenance of immune homeostasis in the gut.

β-Defensins are expressed by most epithelial cells, and their expression is often stimulated by proinflammatory stimuli and infection. They are present in the mucosal secretions of respiratory, gastrointestinal, and urogenital tracts, and in inflamed skin.[@CIT0013]--[@CIT0016] β-Defensins are also expressed by human monocytes, macrophages, and dendritic cells, and are important components of the azurophilic granules of bovine neutrophils.[@CIT0004]

The much rarer θ-defensins are cyclic molecules, produced in neutrophils and monocytes of rhesus macaques through ligation of two α-defensin-like peptides.[@CIT0017] As a result of their cyclic structure, the (moderate) microbicidal activity of θ-defensins is resistant to salt concentration. However, θ-defensins have not been found in humans or other mammals.

Cathelicidins are the other major family of natural HDPs, although they are grouped by their mechanism of production rather than sequence similarity. All cathelicidins are synthesised as inactive precursors, comprising an N-terminal cathelin-like domain followed by the peptide region, and are proteolytically processed to release mature active HDPs.[@CIT0018] Cathelicidins vary in length, sequence, and structure, having extended, α-helical or β-hairpin folds; however, some are short linear molecules (for example, indolicidin, 13 amino acids), and these are ideal starting points for the design of synthetic peptides with optimised biological activity.

Bovine and porcine immune systems produce a large variety of cathelicidins, including bactenecin, indolicidin, PR-39, protegrins, prophenins, and many others.[@CIT0018] In contrast, in humans there is only one known cathelicidin precursor protein hCAP18, which is proteolytically processed to yield mature cathelicidin LL-37 [@CIT0019] and, in the skin, a series of additional proteolytic derivatives with altered activities.[@CIT0020] LL-37 lacks disulphide bonds and is weakly structured in solution, but adopts an a-helical conformation when interacting with lipid bilayers. Mice also have only one cathelicidin precursor, which is processed to produce mature peptide CRAMP, with 67% sequence identity to LL-37.[@CIT0021] LL-37 is found in the secretory granules of neutrophils and other leukocytes,[@CIT0022] and is also produced by mucosal epithelia and keratinocytes.[@CIT0023]--[@CIT0025] The expression of LL-37 is modestly upregulated by proinflammatory stimuli, and is also induced by the HIF-1α and the vitamin D receptor pathways.[@CIT0026]--[@CIT0028]

Many other HDPs that do not belong to the defensin or cathelicidin families have also been characterised in humans and other mammals. Some important examples include: histatins, histidine-rich cationic peptides with antifungal activity present in the saliva;[@CIT0029] dermcidin, an anionic peptide present in human sweat with modest salt-insensitive antimicrobial properties;[@CIT0030] cationic peptide lactoferricin derived from an iron-binding protein lactoferrin and found in mucosal secretions, milk, and in the granules of leukocytes.[@CIT0031]

Biological activities and roles of host defence peptides in immunity {#S0003}
====================================================================

The evolutionarily widespread distribution and the extreme diversity of HDPs highlight their prominent role in immune defences. Historically, this has been attributed to their antimicrobial activity but in recent years potent immunomodulatory properties of HDPs have been characterised and suggested to be an important part of their biological function.[@CIT0019], [@CIT0032] An in-depth understanding of the physiological roles and mechanisms of action of HDPs is crucial for the development of artificial variants with optimised activity for therapeutic applications.

Antimicrobial properties of HDPs are linked to their amphipathic fold, which allows the peptides to interact with lipid bilayers of microorganisms,[@CIT0002] and kill either through membrane disruption or by translocating across the membrane and inhibiting cytosolic targets. Owing to the relatively nonspecific nature of the interactions between HDPs and the anionic lipids of microbial membranes, many peptides have broad antimicrobial properties, targeting Gram-positive and -negative bacteria, fungi, protozoa, and some viruses.[@CIT0001], [@CIT0033] Furthermore, HDPs are highly effective against multidrug-resistant bacterial strains. Peptides can also interact with mammalian membranes and this is at least partly responsible for cytotoxicity of some peptides at high concentrations.[@CIT0034] However, distinct composition of mammalian membranes, with preferential localisation of anionic phospholipids into the inner leaflet, offers some protection. Furthermore, membrane interactions and antimicrobial properties of most HDPs are strongly dependent on the composition of the media, being inhibited by divalent cations and serum.[@CIT0019], [@CIT0014], [@CIT0034] Thus, although HDPs almost certainly function as powerful microbicidal agents in some physiological settings, such as the phagolysosomes of neutrophils, intestinal crypts, and sites of acute inflammation, under other conditions where salt concentrations are high (100 mM monovalent and 2 mM divalent cations) and peptide concentrations are modest, their immunomodulatory activities are almost certainly more physiologically relevant.

A wide range of HDPs from different species have been shown to act as chemoattractants for cells of innate and adaptive immunity. As an example, human cathelicidin LL-37 attracts neutrophils, monocytes, T cells, and mast cells, using formyl peptide receptor-like 1 (FPRL1), and a distinct G~i~-coupled receptor.[@CIT0035], [@CIT0036] Optimal chemotactic activity of LL-37 is observed in a concentration range that can be reached *in vivo* under inflammatory conditions.[@CIT0035] Furthermore, synthetic peptide IDR-1, which is protective in mouse models of bacterial infections, similarly chemoattracts neutrophils, acting through receptor FPRL1.[@CIT0037], [@CIT0038]

Apart from direct chemotactic effects, HDPs also elicit other complex responses in leukocytes and epithelial cells, altering gene expression and behaviour to facilitate and to modulate immune responses ([Figure 1](#F0001){ref-type="fig"}). For example, when LL-37 was used to stimulate primary human monocytes and macrophage cell lines, microarrays demonstrated the induction of a wide range of chemokines, chemokine receptors, and other genes involved in cell adhesion, communication, and motility.[@CIT0040] In particular, induction of chemokines IL8, Gro-α, MCP1, MIP-1β, and MIP-3α, but not proinflammatory cytokines, was consistently seen with a wide range of natural and synthetic peptides.

![Immunomodulatory activity of host defence peptides: human cathelicidin LL-37. LL-37 induces global alterations in gene expression in monocytes, signalling through p38, ERK, PI3K, and NF-kB pathways, and promoting expression of chemokines and other genes involved in cell communication and motility.[@CIT0032], ([@CIT0039]) LL-37 also acts as a direct chemoattractant for monocytes, neutrophils, T cells, and mast cells through the FPRL1 receptor,[@CIT0035] and an unknown Gi-coupled receptor.[@CIT0036] LL-37 is also strongly anti-endotoxic and inhibits the production of proinflammatory cytokines in monocytes in response to LPS,[@CIT0040] and also the maturation of monocyte-derived dendritic cells by TLR ligands.[@CIT0041] In contrast, LL-37 pretreatment of monocytes modulates the process of dendritic cell differentiation, enhancing their function^;^ [@CIT0042] and in plasmacytoid dendritic cells (pDCs) LL-37 promotes responses to TLR9 ligands.[@CIT0043] Other activities of LL-37 include the promotion of antimicrobial functions of neutrophils,[@CIT0044] mast cell degranulation,[@CIT0045] and IL-1β processing in LPS-primed monocytes.[@CIT0046] LL-37 also affects neutrophil and epithelial cell apoptosis^.^, [@CIT0047]--[@CIT0049] In keratinocytes, LL-37 induces IL8, and promotes migration and wound healing, and these activities depend on ADAM family metalloproteinase, EGFR and FPRL1.[@CIT0050], ([@CIT0051]) In airway epithelial cells, LL-37 activates p38 and ERK pathways and induces chemokine secretion, and this is reported to be mediated by receptors: FPRL1,[@CIT0035], ([@CIT0052]) ADAM family metalloproteinase and EGFR,[@CIT0053] and through active peptide internalisation.[@CIT0052] LL-37 also promotes angiogenesis, through FPRL1 receptor on vascular endothelium^.^, [@CIT0054]](EHTJ-2-e1-g001){#F0001}

HDPs also act as powerful modulators of cellular responses to inflammatory stimuli. Thus, LL-37 can inhibit secretion of inflammatory cytokines in response to lipoploysaccharide,[@CIT0040] and offer some protection in experimental endotoxaemia in mice.[@CIT0032] Direct interaction with lipoploysaccharide accounts for only a fraction of the anti-endotoxic activity of LL-37, and transcriptional profiling of human monocytes stimulated with lipoploysaccharide, with and without LL-37, established a complex pattern of modulation of the lipoploysaccharide response, with a profound inhibition of proinflammatory genes, but retention of expression of chemotactic mediators and negative regulators of TLR signalling.[@CIT0040] On the basis of these studies, we have proposed that at least in some physiological settings LL-37 and possibly other peptides act to promote localised immunity to infection, while preventing systemic hyperinflammatory response.

In contrast to the well-established anti-endotoxic activity of some peptides, the effects of peptides on cellular responses to other proinflammatory stimuli are cell type and stimulus dependent. This is well illustrated by the effects of peptides on dendritic cells. Immature monocyte-derived dendritic cells generated in the presence of LL-37 have increased phagocytic activity and, after maturation, show enhanced capacity to induce Th1-polarised immunity.[@CIT0042] In contrast, simultaneous treatment of immature monocyte-derived dendritic cells with LL-37 and TLR ligands inhibits dendritic cell maturation.[@CIT0041] In plasmacytoid dendritic cells, LL-37 strongly augments responses to host and bacterial DNA, and this activity may contribute to the pathology of psoriasis.[@CIT0043] Furthermore, murine β-defensin 2 was reported to act as an endogenous TLR4 ligand, promoting dendritic cell maturation and Th1 polarisation of immune response.[@CIT0055]

The biological importance of HDPs in mammalian immunity has been investigated in several mouse models. The role of cryptidins in the gut is highlighted by the following reports: MMP7-knockout mice lacking mature cryptidins and NOD2-null mice with reduced cryptidin production are more susceptible to oral challenges with *Escherichia coli* and *Listeria*,[@CIT0010], [@CIT0056] whereas transgenic mice with a Paneth cellspecific expression of human cryptidin HD5 are more resistant to oral challenges with *Salmonella*.[@CIT0057] The role of cathelicidins in the immune defences of epithelial surfaces is addressed by the studies of CRAMP-null mice, which develop necrotic skin infections when challenged with group A *Streptococcus*,[@CIT0058] and are also more susceptible to infections of the urinary tract.[@CIT0059]

Dysregulation of HDP production is also implicated in the pathology of a number of human diseases. In the specific granule deficiency and morbus Kostmann syndromes, deficiencies in neutrophil HDPs (and other proteins of neutrophil granules) are associated with persistent bacterial infections.[@CIT0060], [@CIT0061] Reduced HDP production in the skin is also associated with human disorders, with reduced LL-37 and β-defensin levels in atopic dermatitis being linked to frequent skin infections.[@CIT0062] In contrast, abnormally high levels and altered proteolytic processing of cathelicidins are implicated in skin inflammatory conditions of rosacea and psoriasis.[@CIT0043], [@CIT0063] Disruption of HDP production and function at mucosal surfaces is also implicated in human pathologies, in particular in Crohn\'s disease and cystic fibrosis. It was suggested that the bacterial colonisation of the airways of cystic fibrosis patients, is at least in part, the result of inactivation of antimicrobial peptides by the high salt contents of airway fluids in cystic fibrosis.[@CIT0064], [@CIT0065] Mutations in NOD2, associated with Crohn\'s disease, result in impaired production of cryptidins and this was proposed to contribute to the chronic intestinal inflammation by disrupting the interactions between the immune system and the microflora.[@CIT0012], [@CIT0056]

In summary, HDPs with their direct antimicrobial properties and diverse immunomodulatory activities play an important role in mammalian immunity to infections and immune homoeostasis. The potential for these activities for clinical and commercial purposes remains to be fully explored.

Therapeutic potential of host defence peptides {#S0004}
==============================================

With increasing bacterial resistance to conventional antibiotics,[@CIT0066] there is a growing interest in exploiting the biological activities of HDPs to target multidrug-resistant pathogens.[@CIT0003] However, despite much progress in the laboratory, so far only a few HDP-derived compounds have progressed into the clinic, with most clinical trials focusing on topical rather than systemic applications ([Table 2](#T0002){ref-type="table"}).

###### 

Peptides and peptidomimetics in commercial development

  *Company*                                            *Drug*                                             *Stage of development*   *Medical use*
  ---------------------------------------------------- -------------------------------------------------- ------------------------ ---------------------------------------------------------------------------------
  AM-Pharma (Bunnik, The Netherlands)                  hLF-1-11                                           Phase II                 Allogeneic bone marrow stem cell transplantation-associated infections
  BioLineRx Ltd (Jerusalem, Israel)                    BL2060                                             Preclinical              Gram-negative pneumonia
  Ceragenix (Denver, Colorado, USA)                    CSA-13[^a^](#TF0001){ref-type="table-fn"}/CGX313   Preclinical              Prevention of nasal carriage of *Staphylococcus*
  Helix Biomedix (Bothell, Washington, USA)            Lipohexapeptide                                    Preclinical              Anti-infective
  Inimex (Burnaby, British Columbia, Canada)           IMX942                                             Preclinical              Immunomodulation; treatment of fevers and neutropaenia in chemotherapy patients
  Migenix Inc. (Vancouver, British Columbia, Canada)   CPI/MX-226                                         Phase IIIb               Prevention of catheter-related infections
                                                       CLS001                                             Phase II+                Inflammation in Rosacea
  Novozymes A/S (Bagsvaerd, Denmark)                   Plectasin                                          Preclinical              Systemic anti-Gram positive, especially pneumococcal infections
  Pacgen (Vancouver, British Columbia, Canada)         PAC113                                             Phase IIb                Oral candidiasis
  Polymedix (Radnor, Philedelphia, USA)                PMX30063[^b^](#TF0002){ref-type="table-fn"}        Phase I                  Systemic anti-infective peptidomimetic

A cationic steroid antibiotic.

Non-peptidic structural analogue of an antimicrobial peptide.

This is a listing of known antimicrobial and/or immunomodulatory agents in development and/or clinical trials within private companies. Only agents currently in clinical trials or likely to enter the clinic soon are recorded. This information is based on a prior review,[@CIT0003] updated by us primarily from company press releases and public presentations. Several peptides that went through clinical trials but were not approved[@CIT0003] or polymyxins and gramicidin S that are generic anti-infectives that have long been available are not described

The traditional approach to developing HDP-based therapeutics has focused on the antimicrobial properties of natural peptides. Various methodologies for identifying, selecting, or designing highly active artificial antimicrobial peptides have been developed. One approach is to screen extensive libraries of semirandom peptides for bactericidal properties.[@CIT0067], [@CIT0068] Alternatively, systematic substitutions in the amino-acid sequence of natural antimicrobial HDPs can be used to improve their activity. For example, combining highthroughput peptide synthesis on cellulose sheets with automated screening for antimicrobial properties using a luciferase reporter system allowed the development of bactenecin derivatives with dramatically improved activity.[@CIT0069] Furthermore, several computer-aided approaches to analyse structure--function relationships in natural and artificial peptide libraries permitted the prediction of peptide activity and design of novel peptides with stronger antimicrobial properties.[@CIT0070], [@CIT0071]

One of the limitations that need to be overcome before peptides can be widely used in the clinic is the high cost of peptide production. Costs can be reduced to some extent by focusing on linear peptides of minimal length, and truncated derivatives of bactenecin and indolicidin with lengths of 8--12 amino acids are good candidates.[@CIT0069] However, more complex structures can be effectively generated on a large scale using recombinant technology[@CIT0072] and should certainly be pursued. Lantibiotics are bacterial peptides with antimicrobial properties produced on an industrial scale for use as food preservatives. They make up one class of such compounds.[@CIT0073] Their potential therapeutic value certainly warrants further investigation. Another approach to reducing the costs of peptide therapeutics is to improve peptide stability and pharmacokinetics, thus decreasing the required dose. Currently, this is investigated with protease-resistant D-amino acid peptides and various peptidomimetics.[@CIT0003]

Concerns have been raised that a widespread use of HDPs in the clinic would select for pathogens resistant to natural immune defences. Indeed, many bacterial species already possess modestly effective resistance mechanisms, including peptide degradation, sequestration, efflux, and chemical modifications of cell walls and membranes to reduce HDP binding;[@CIT0074], [@CIT0075] resistance to HDPs can be selected in the laboratory.[@CIT0076] Nevertheless, HDPs are less prone to inducing resistance than conventional antibiotics because they often use several microbicidal mechanisms simultaneously, target ing many microbial systems with low affinity rather than having one specific target.[@CIT0075] Also, because of the diverse mechanisms of peptide action, the use of synthetic peptides that do not occur in nature could partly alleviate the problem of resistance to natural HDPs. Finally, immunomodulatory peptides that act on the host rather than on the pathogen offer a unique opportunity to minimise the direct selective pressures for pathogen resistance.

Recently, such an immunomodulatory peptide, an innate defence regulator IDR-1, was shown to protect mice against bacterial infections, including infections with multidrugresistant pathogens, and this provides an important proof of principle for the immunomodulatory approach.[@CIT0038] The peptide was shown to act as a neutrophil chemoattractant[@CIT0037] and furthermore to induce chemokine production and promote cell recruitment *in vitro* and *in vivo*; these activities may account for some of its protective effects. Importantly this peptide, as well as many natural HDPs, exerts anti-inflammatory and anti-endotoxic effects at the same time as promoting local clearance of infection.[@CIT0038], [@CIT0040] Thus, unlike other treatments aimed at boosting the immune system, such peptides can offer protection without the risk of inducing dangerous hyperinflammatory states. In the immediate future, the field of immunomodulatory peptide therapeutics faces the challenges of developing highthroughput screens for immunomodulatory activity, and also of firmly defining which *in vitro* activities correlate with the protection against infection and other desirable biological outcomes *in vivo.* Furthermore, other activities of HDPs, such as their roles in wound healing and angiogenesis, require further investigation to assess their potential therapeutic value.[@CIT0054]

Conclusion {#S0005}
==========

Over the course of evolution, nature has created an impressive arsenal of HDPs with extreme diversity in structure and biological activity. These can serve as excellent templates for development of both antimicrobial and immunomodulatory compounds, often combining both activities in the same molecule. The potential therapeutic value of such compounds is just beginning to be fully recognised. These compounds can be used in combination with conventional antibiotics, and also to target resistant pathogens where conventional antibiotics fail. Some peptides may even have potential against diseases of unknown aetiology (emerging infectious diseases), as their spectrum of activity is often very broad and may involve stimulation of the immune response of the host rather than targeting the pathogen. Importantly, immunomodulatory peptides that target the host immune system rather than the pathogen also offer an excellent opportunity to minimise the risks of pathogen resistance to these compounds. The current challenge is to develop new biologically active synthetic peptides or mimetics thereof with improved pharmacokinetics, low toxicity, and low manufacturing costs for both topical and systemic applications.
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